Humana (NYSE:HUM) Releases FY24 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $16.00 for the period, compared to the consensus estimate of $16.34.

Humana Trading Up 1.3 %

Shares of NYSE HUM traded up $4.64 during mid-day trading on Friday, hitting $363.62. The stock had a trading volume of 1,076,306 shares, compared to its average volume of 1,396,067. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.67 and a current ratio of 1.66. Humana has a 1 year low of $298.61 and a 1 year high of $530.54. The business has a 50 day moving average price of $367.90 and a two-hundred day moving average price of $347.35. The firm has a market cap of $43.78 billion, a P/E ratio of 22.64, a price-to-earnings-growth ratio of 2.09 and a beta of 0.51.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same period in the previous year, the firm earned $8.94 earnings per share. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities analysts anticipate that Humana will post 16.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HUM. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Humana from $341.00 to $349.00 and gave the company a hold rating in a research report on Friday. Robert W. Baird began coverage on shares of Humana in a research report on Thursday, May 30th. They set a neutral rating and a $374.00 price objective on the stock. Cantor Fitzgerald reissued a neutral rating and set a $360.00 price objective on shares of Humana in a research report on Tuesday, July 23rd. Wells Fargo & Company dropped their target price on shares of Humana from $413.00 to $350.00 and set an overweight rating on the stock in a report on Monday, April 8th. Finally, Truist Financial boosted their target price on shares of Humana from $355.00 to $400.00 and gave the company a hold rating in a report on Monday, July 15th. Fourteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of Hold and an average target price of $403.55.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.